David SARFATI MIZRAHI,Ernesto SOTO PRIANTE,Bernardo LOZANO DUBERNARD
申请号：
MX2017001742
公开号：
MX2017001742A
申请日:
2015.08.06
申请国别(地区):
MX
年份:
2017
代理人:
摘要：
A description is given of a recombinant vaccine that comprises a sero type 9 avian adenovirus vector (FAdV-9) with the insertion of at least one exogenous nucleotide sequence that codes for at least one antigen of a disease of interest and that replaces the non-essential region of the adenovirus genome, and a vehicle, adjuvant and/or excipient that is pharmaceutically acceptable, wherein the at least one exogenous nucleotide sequence that codes for at least one antigen of a disease of interest and that replaces the non-essential region of the adenovirus genome is located between nucleotides 491-2782. The vector of this vaccine is stable for production on an industrial scale. Likewise, even when this vaccine is administered in combination with a vaccine against Marek's disease, the two vaccines produce an adequate immune response that is unaffected by interference between them. Similarly, the efficacy of the recombinant vaccine is unaffected by maternal antibodies and is capable of inducing a protective response that is both early and long-lasting, even with a single application.Se describe una vacuna recombinante que comprende un vector de adenovirus aviar serotipo 9 (FAdV-9) que tiene insertada por lo menos una secuencia de nucleotidos exogena que codifica para por lo menos un antigeno de una enfermedad de interes y que reemplaza la region no esencial del genoma del adenovirus, y un vehiculo, adyuvante y/o excipiente farmaceuticamente aceptable, en donde la por lo menos una secuencia de nucleotidos exogena que codifica para por lo menos un antigeno de una enfermedad de interes y que reemplaza la region no esencial del genoma del adenovirus se localiza entre los nucleotidos 491-2782； el vector de esta vacuna es estable para produccion a escala industrial； asimismo, aun cuando esta vacuna se administra en combinacion con una vacuna contra la enfermedad de Marek, ambas producen una respuesta inmune adecuada que no se ve afectada por la interferencia entre ellas； de
